Patient Satisfaction And Disease Control In Patients With Systemic Lupus Erythematosus Is Not Affected By Switching From Intravenous Belimumab To Subcutaneous Injections

PURPOSE: Since the launch of belimumab in 2011, the BLyS antibody has been increasingly used in the therapy of systemic Lupus erythematosus (SLE). Comparative studies showed that the intravenous (i.v.) and subcutaneous (s.c.) administration forms do not differ in their efficacy. Since the approval o...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Patient Prefer Adherence
Autors principals: Mucke, Johanna, Brinks, Ralph, Fischer-Betz, Rebecca, Richter, Jutta G, Sander, Oliver, Schneider, Matthias, Chehab, Gamal
Format: Artigo
Idioma:Inglês
Publicat: Dove 2019
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6839583/
https://ncbi.nlm.nih.gov/pubmed/31806937
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PPA.S227208
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars